Keywords: aeterna, 3rd, qtr, loss, quadruples, costs, canadian
AEterna's 3rd qtr loss quadruples on costs
Article | 19 November 2007
Canadian biopharmaceutical company AEterna Zentaris reported a third quarter 2007 loss of $8.7 million, up from the $1.6 million deficit it posted in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
